Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Support MFO
Donate through PayPal
Actively Managed Funds Roar Back — Here Are the Best Of 2015
@Ted, congratulation to your fund pick - 70%! Unlike the late 90's, many biotech firms are actually producing products cannot be manufactured by traditional drug companies while making good profits. Like you I also invest with T. Rowe Price Health Science and it has doing very well over the last decade.
I tend to shy away from Fidelity sector funds due to the rapid change of fund managers. Many have tenure less than 2 years of experience that implies that is the training ground of young and inexperience managers. If I wish to play in that space I would pick individual stocks similar to what Scott is doing.
Point taken about turnover, but I would much much rather have some smart former analyst kid spend two years doing that, picking individual stocks in a given area based on his and his team's researches, than trust myself to do it.
Comments
The biotech companies within healthcare sector has been doing well in the last several years, not just 2015.
Regards,
Ted
FBTCX Long-Term Performance;
http://performance.morningstar.com/fund/performance-return.action?t=FBTCX®ion=usa&culture=en_US
I tend to shy away from Fidelity sector funds due to the rapid change of fund managers. Many have tenure less than 2 years of experience that implies that is the training ground of young and inexperience managers. If I wish to play in that space I would pick individual stocks similar to what Scott is doing.